BioReliance Schedules Conference Call to Discuss First Quarter Financial Results

Apr 19, 2001, 01:00 ET from BioReliance Corporation

    ROCKVILLE, Md., April 19 /PRNewswire/ -- BioReliance Corporation
 (Nasdaq: BREL) today announced that it will release its first quarter
 financial results for the period ended March 31, 2001, on April 26, 2001.
 In conjunction with its release, the Company will host a conference call
 to review the Company's financial and operating results on April 27, 2001,
 at 10:00 a.m. Eastern Standard Time.
     Individuals wishing to participate in the conference call should call
 303-224-6997.  For interested individuals unable to join the call, a replay
 will be available through May 4, 2001, by dialing 303-804-1727, passcode
 1002980.  The conference call will also be broadcast live over the Internet
 and can be accessed by all interested parties at www.vcall.com .
     BioReliance Corporation is a leading contract service organization
 providing testing, development and manufacturing services for biologics and
 other biomedical products to biotechnology and pharmaceutical companies
 worldwide.  The Company believes that it is the largest provider of
 outsourcing services focused on the expanding biologics sector of the
 pharmaceutical industry.  Headquartered in Rockville, MD, the Company also
 has testing and manufacturing facilities in Stirling, United Kingdom and
 Heidelberg, Germany.
     To receive BioReliance's latest news and review other corporate
 developments, please visit our web site at http://www.bioreliance.com .
     Certain statements made in the conference call may be "forward-looking
 statements" within the meaning of the Private Securities Litigation Reform Act
 of 1995 (the "Act").  Forward-looking statements include, without limitation,
 any statement that may predict, forecast, indicate, or imply future results,
 performance, or achievements, and may contain the words "believe,"
 "anticipate," "expect," "estimate," "project," "will be," "will continue,"
 "will likely result," or similar words or phrases.  Forward-looking statements
 involve risks and uncertainties which may cause actual results to differ
 materially from the forward-looking statements.  The risks and uncertainties
 are detailed from time to time in reports filed by BioReliance with the
 Securities and Exchange Commission, including in its Forms 10-K and 10-Q.  New
 risk factors emerge from time to time and it is not possible for management to
 predict all such risk factors, nor can it assess the impact of all such risk
 factors on the Company's business or the extent to which any factor, or
 combination of factors, may cause actual results to differ materially from
 those contained in any forward-looking statements.  Given these risks and
 uncertainties, investors should not place undue reliance on forward-looking
 statements as a prediction of actual results.
 
 

SOURCE BioReliance Corporation
    ROCKVILLE, Md., April 19 /PRNewswire/ -- BioReliance Corporation
 (Nasdaq: BREL) today announced that it will release its first quarter
 financial results for the period ended March 31, 2001, on April 26, 2001.
 In conjunction with its release, the Company will host a conference call
 to review the Company's financial and operating results on April 27, 2001,
 at 10:00 a.m. Eastern Standard Time.
     Individuals wishing to participate in the conference call should call
 303-224-6997.  For interested individuals unable to join the call, a replay
 will be available through May 4, 2001, by dialing 303-804-1727, passcode
 1002980.  The conference call will also be broadcast live over the Internet
 and can be accessed by all interested parties at www.vcall.com .
     BioReliance Corporation is a leading contract service organization
 providing testing, development and manufacturing services for biologics and
 other biomedical products to biotechnology and pharmaceutical companies
 worldwide.  The Company believes that it is the largest provider of
 outsourcing services focused on the expanding biologics sector of the
 pharmaceutical industry.  Headquartered in Rockville, MD, the Company also
 has testing and manufacturing facilities in Stirling, United Kingdom and
 Heidelberg, Germany.
     To receive BioReliance's latest news and review other corporate
 developments, please visit our web site at http://www.bioreliance.com .
     Certain statements made in the conference call may be "forward-looking
 statements" within the meaning of the Private Securities Litigation Reform Act
 of 1995 (the "Act").  Forward-looking statements include, without limitation,
 any statement that may predict, forecast, indicate, or imply future results,
 performance, or achievements, and may contain the words "believe,"
 "anticipate," "expect," "estimate," "project," "will be," "will continue,"
 "will likely result," or similar words or phrases.  Forward-looking statements
 involve risks and uncertainties which may cause actual results to differ
 materially from the forward-looking statements.  The risks and uncertainties
 are detailed from time to time in reports filed by BioReliance with the
 Securities and Exchange Commission, including in its Forms 10-K and 10-Q.  New
 risk factors emerge from time to time and it is not possible for management to
 predict all such risk factors, nor can it assess the impact of all such risk
 factors on the Company's business or the extent to which any factor, or
 combination of factors, may cause actual results to differ materially from
 those contained in any forward-looking statements.  Given these risks and
 uncertainties, investors should not place undue reliance on forward-looking
 statements as a prediction of actual results.
 
 SOURCE  BioReliance Corporation